Embecta Corp. EMBC Syringes — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Embecta Corp. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Embecta Corp.'s syringes — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Embecta Corp.'s syringes — revenue?
- Embecta Corp. (EMBC) reported syringes — revenue of $26.3M in Q1 2026.
- How has Embecta Corp.'s syringes — revenue changed year-over-year?
- Embecta Corp.'s syringes — revenue decreased by 8.7% year-over-year, from $28.8M to $26.3M.
- What is the long-term trend for Embecta Corp.'s syringes — revenue?
- Over 3 years (2022 to 2025), Embecta Corp.'s syringes — revenue has grown at a -7.2% compound annual growth rate (CAGR), from $156M to $124.6M.
- What does syringes — revenue mean?
- This metric represents the total gross sales generated from the company's dedicated syringes product line. It serves as a key indicator of market demand and adoption for this specific medical device category within the broader clinical therapy portfolio. Tracking these revenues helps investors assess the performance and lifecycle maturity of the company's foundational injection technology offerings.